Extracellular Matrix News Volume 12.05 | Feb 11 2021

May 12, 2022

2020-11-02 | ECM 12.05

Extracellular Matrix News by STEMCELL Technologies

Vol. 12.05 – 11 February, 2021

TOP STORY

Molecular Characterization of the Human Kidney Interstitium in Health and Disease

The diabetic interstitium was enriched for ECM organization and small-molecule catabolism. Cell type markers with unchanged expression and those down-regulated in diabetic nephropathy were identified.
[Science Advances]

Full Article

As a scientist, how you separate the facts from the claims is just as important as how you separate your cells. See for yourself.

PUBLICATIONSRanked by the impact factor of the journal

Mesenchymal Stromal Cell Delivery of Oncolytic Immunotherapy Improves CAR-T Cell Antitumor Activity

The authors describe how MSCs could be used to systemically deliver a binary vector containing an oncolytic adenovirus (Ad) together with a helper dependent Ad that expresses IL-12 and checkpoint PD-L1 blocker.
[Molecular Therapy]

Abstract Graphical Abstract

Dynamically Remodeled Hepatic Extracellular Matrix Predicts Prognosis of Early-Stage Cirrhosis

Investigators systematically analyzed proteomics of decellularized hepatic matrix and identified four unique clusters of ECM proteins at tissue damage/inflammation, transitional ECM remodeling or fibrogenesis stage in carbon tetrachloride-induced liver fibrosis.
[Cell Death & Disease]

Full Article

Micro-Laminin Gene Therapy Can Function as an Inhibitor of Muscle Disease in the dy^W Mouse Model of MDC1A

LAMA2 encodes laminin-α2, a subunit of the trimeric laminin-211 ECM protein that is the predominant laminin expressed in skeletal muscle. LAMA2 expression stabilized skeletal muscle, in part by binding membrane receptors via its five globular (G) domains. Researchers tested the therapeutic efficacy of these G1-G5 domains in the dyW mouse model for MDC1A.
[Molecular Therapy-Methods & Clinical Development]

Abstract Graphical Abstract

Computational 4D-OCM for Label-Free Imaging of Collective Cell Invasion and Force-Mediated Deformations in Collagen

Scientists’ multi-day, time-lapse imaging data provided detailed visualizations of evolving spheroid morphology, collagen degradation, and collagen deformation, all using label-free scattering contrast.
[Scientific Reports]

Full Article

Molecular Profiling of Epigenetic Landscape of Cancer Cells during Extracellular Matrix Detachment

Researchers showed both EZH2 expression and its enzymatic activity were significantly increased in ECM detached cancer cells when compared to the attached cells. Inhibition of EZH2 resulted in a significant reduction in cell proliferation, spheroids size, and induction in apoptosis in ECM detached cells.
[Scientific Reports]

Full Article

IL-6 and IL-8, Secreted by Myofibroblasts in the Tumor Microenvironment, Activate HES1 to Expand the Cancer Stem Cell Population in Early Colorectal Tumor

The authors investigated the cancer stem cell‐promoting effect of factors released from myofibroblasts into the microenvironment of early colorectal cancer tumors and its molecular mechanism.
[Molecular Carcinogenesis]

Abstract

Watch 'collaborating to accelerate COVID-19 research'

REVIEWS

Location, Location, Location: How the Tissue Microenvironment Affects Inflammation in RA

Emerging evidence indicates an important role for the tissue microenvironment in the pathogenesis of rheumatoid arthritis (RA). Each tissue is made up of cells surrounded and supported by a unique ECM. These complex molecular networks define tissue architecture and provide environmental signals that program site-specific cell behavior.
[Nature Reviews Rheumatology]

Abstract

Fueling Cell Invasion through Extracellular Matrix

Investigators provide an overview of the challenges of examining ATP generation and delivery within invading cells and how recent studies using diverse invasion models, experimental approaches, and energy biosensors are revealing that energy metabolism is an integral component of cell invasive behavior that is dynamically tuned to overcome the ECM environment.
[Trends in Cell Biology]

Abstract

Interplay between Tumor Microenvironment and Partial EMT as the Driver of Tumor Progression

The authors focus on important role of tumor-intrinsic factors and tumor microenvironment in driving partial epithelial-to-mesenchymal transition (pEMT) and emphasize that engineered controlled microenvironments are instrumental to provide mechanistic insights into pEMT biology.
[iScience]

Abstract Graphical Abstract

INDUSTRY AND POLICY NEWS

Arch Oncology to Collaborate with Merck on Phase I/II Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA^® (pembrolizumab) in Patients with Select Solid Tumors

Arch Oncology, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck. Under this collaboration, Arch Oncology is expanding its ongoing Phase I/II clinical trial to evaluate AO-176, the Company’s novel anti-CD47 antibody, in combination with KEYTRUDA^® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with select solid tumors.
[Arch Oncology, Inc.]

Press Release

FEATURED EVENT

Molecular Characterization of the Human Kidney Interstitium in Health and Disease

Mesenchymal Stromal Cell Delivery of Oncolytic Immunotherapy Improves CAR-T Cell Antitumor Activity

Dynamically Remodeled Hepatic Extracellular Matrix Predicts Prognosis of Early-Stage Cirrhosis

Micro-Laminin Gene Therapy Can Function as an Inhibitor of Muscle Disease in the dy^W Mouse Model of MDC1A

Computational 4D-OCM for Label-Free Imaging of Collective Cell Invasion and Force-Mediated Deformations in Collagen

Molecular Profiling of Epigenetic Landscape of Cancer Cells during Extracellular Matrix Detachment

IL-6 and IL-8, Secreted by Myofibroblasts in the Tumor Microenvironment, Activate HES1 to Expand the Cancer Stem Cell Population in Early Colorectal Tumor

Location, Location, Location: How the Tissue Microenvironment Affects Inflammation in RA

Fueling Cell Invasion through Extracellular Matrix

Interplay between Tumor Microenvironment and Partial EMT as the Driver of Tumor Progression

Arch Oncology to Collaborate with Merck on Phase I/II Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA^® (pembrolizumab) in Patients with Select Solid Tumors

ISEV2021 Annual Meeting

> See All Events

Postdoctoral Research Fellow – Scaffold-Based 3D Model of Neurodegeneration

Postdoctoral Fellow – Osteoarthritis

Training Fellowships – Glycosciences

Research Associate – Proteome Modulation and Cancer Microenvironment Signaling

Postdoctoral Position – Tumor Microenvironment

> See All Jobs